Clinical Trials Logo

Heart Valve Diseases clinical trials

View clinical trials related to Heart Valve Diseases.

Filter by:

NCT ID: NCT04916418 Active, not recruiting - Clinical trials for Coronary Artery Disease

Postoperative Pain Relief With Transversus Thoracis Muscle Plane Block After Cardiac Surgery

TTPcat
Start date: October 15, 2021
Phase: Phase 4
Study type: Interventional

This study aims to investigate the effect of transversus thoracis muscle plane block (TTP), using repeated boluses of ropivacaine via catheter, on postoperative pain and oxycodone consumption after elective cardiac surgery with sternotomy.

NCT ID: NCT04464876 Active, not recruiting - Clinical trials for Mitral Regurgitation

SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

Start date: August 19, 2020
Phase: N/A
Study type: Interventional

This study is a prospective, single-arm, multi-center feasibility clinical study of the SATURN TA System for the treatment of NYHA Class ≥ II patients with severe functional mitral regurgitation who are not suitable for surgical treatment following Heart Team assessment.

NCT ID: NCT04223219 Active, not recruiting - Clinical trials for Coronary Artery Disease

Different Modalities of Analgesia in Open Heart Surgeries in Mansoura University

Start date: December 10, 2019
Phase: Phase 4
Study type: Interventional

Cardiac surgery is associated with post-operative pain which is one of the major problems and remains one of the most controversial issues. Inadequate pain control after cardiac surgery increases the incidence of development of many complications. Intravenous opioids are commonly used for postoperative analgesia either on demand "physician or nurse-controlled" or patient -controlled. Multimodal opioid sparing analgesia has become frequently used, These techniques can be achieved with Dexmedetomidine, low-dose ketamine and magnesium. The study hypotheses that control of perioperative quality of pain with opioid sparing medications may improve analgesia and patient outcome.

NCT ID: NCT04221490 Active, not recruiting - Clinical trials for Cardiovascular Diseases

2019-06 TRISCEND Study

Start date: May 6, 2020
Phase: N/A
Study type: Interventional

Prospective, multi-center study to assess safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System

NCT ID: NCT04160130 Active, not recruiting - Clinical trials for Aortic Valve Stenosis

RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)

RHEIA
Start date: November 29, 2019
Phase: N/A
Study type: Interventional

Purpose of this prospective, randomized, controlled, multi-center study is to evaluate the safety and efficacy of Transcatheter Aortic Valve Implantation (TAVI) as compared to surgical aortic valve replacement (SAVR) in female patients with severe symptomatic aortic stenosis. Patients will be randomized 1:1 to receive either TAVI or SAVR aortic valve replacement. For TAVI procedure, Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems will be sued, for SAVR any commercially available surgical bioprosthetic valve. Patients will undergo the following visits: Screening, Procedure, Post Procedure, Discharge, 30 day, 6 months (telephone contact) and 1 year.

NCT ID: NCT03810820 Active, not recruiting - Clinical trials for Aortic Valve Stenosis

Remote ECG Monitoring of TAVI Patients

Start date: June 20, 2018
Phase: N/A
Study type: Interventional

After surgery, patients who undergo transcatheter aortic valve implantation (TAVI) are at risk of developing cardiac arrhythmias such as heart blocks and atrial fibrillation. Current practice is to monitor TAVI patients in hospital for 2-8 days post procedure using scarce and expensive hospital telemetry beds. This study will use a new monitoring service called mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS) to risk stratify patient pre-TAVI and provide an added layer of monitoring that would support earlier discharge of suitably identified patients 24-hours post TAVI. The study will assess whether this strategy will significantly reduce the pressure on hospital resources while improving patient outcomes and experience.

NCT ID: NCT03674593 Active, not recruiting - Clinical trials for Degenerative Mitral Valve Disease

Clinical and Fundamental Aspects of Prosthetics and Translocation of Mitral Valve Chordae

Start date: July 9, 2018
Phase: N/A
Study type: Interventional

The study compares the efficacies of two surgical procedures for the treatment of mitral valve prolapse due to myxomatous degeneration of the mitral valve: the chordae replacement and the translocation of secondary mitral valve chordae.

NCT ID: NCT03661398 Active, not recruiting - Clinical trials for Mitral Regurgitation

Caisson Transcatheter Mitral Valve Replacement (TMVR)

INTERLUDE
Start date: July 20, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety and performance of Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of severe, symptomatic mitral regurgitation (MR).

NCT ID: NCT03635424 Active, not recruiting - Clinical trials for Bicuspid Aortic Valve

Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

Start date: October 30, 2018
Phase: N/A
Study type: Interventional

The objective of the trial is to evaluate the procedural safety and efficacy of the Medtronic TAVR system in patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR

NCT ID: NCT03539458 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification

Start date: October 10, 2018
Phase: N/A
Study type: Interventional

This study is a prospective, single-arm, multi-center feasibility clinical study of the Tendyne Mitral Valve System for the treatment of eligible subjects with symptomatic, severe mitral regurgitation and severe mitral annular calcification (MAC). Subjects satisfying the study inclusion/exclusion criteria will undergo a procedure to implant the Tendyne mitral valve replacement device.